Market Overview

JP Morgan Says Jazz Pharmaceuticals Positioned For 'Organic Growth And Acquisition'

Share:
Related JAZZ
Heavy News Day For Several Biotech Stocks
8 Stories JP Morgan Is Watching Today
Jazz Pharmaceuticals Is Undervalued (Seeking Alpha)

Shares of Jazz Pharmaceuticals (NASDAQ: JAZZ) are up almost 20 percent over the past five trading sessions.

JP Morgan started coverage of the company with an Overweight rating and $190 price target.

"In the context of an ongoing wave of consolidation in the specialty pharmaceuticals sector, we see Jazz as well positioned from both an organic growth and acquisition standpoint," writes analyst Jessica Fye.

Related Link: Leerink Says Tekmir Is 'Uniquely Positioned'

JP Morgan further comments that the company is diversifying away from from its core asset with acquisitions. The company has a borrowing allowance of $3 billion.

On Tuesday, Dow Jones reported Allergan (NYSE: AGN) is interested in purchasing Salix Pharmaceuticals (NASDAQ: SLXP), a competitor in the acquisition space. This news moved Jazz almost four percent higher to $158.14.

Latest Ratings for JAZZ

DateFirmActionFromTo
Feb 2015BMO CapitalInitiates Coverage onOutperform
Nov 2014CitigroupMaintainsBuy
Nov 2014Stifel NicolausMaintainsBuy

View More Analyst Ratings for JAZZ
View the Latest Analyst Ratings

Posted-In: Jessica Fye JP MorganAnalyst Color Price Target Initiation Analyst Ratings

 

Related Articles (JAZZ + AGN)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→